These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 22919717)
21. [Contributions of SGLT-2 and new drugs under investigation]. Mediavilla Bravo JJ Semergen; 2014 Jul; 40 Suppl 2():34-40. PubMed ID: 25311718 [TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of thiophene-C-glucosides as sodium-dependent glucose cotransporter 2 inhibitors. Sakamaki S; Kawanishi E; Koga Y; Yamamoto Y; Kuriyama C; Matsushita Y; Ueta K; Nomura S Chem Pharm Bull (Tokyo); 2013; 61(10):1037-43. PubMed ID: 24088695 [TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
24. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Riser Taylor S; Harris KB Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749 [TBL] [Abstract][Full Text] [Related]
25. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314 [TBL] [Abstract][Full Text] [Related]
26. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210 [TBL] [Abstract][Full Text] [Related]
27. Clinical implication of SGLT2 inhibitors in type 2 diabetes. Kim GW; Chung SH Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857 [TBL] [Abstract][Full Text] [Related]
28. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006 [TBL] [Abstract][Full Text] [Related]
29. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Vallon V Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005 [TBL] [Abstract][Full Text] [Related]
30. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors. Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172 [TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Neumiller JJ; White JR; Campbell RK Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482 [TBL] [Abstract][Full Text] [Related]
32. No Cytotoxic and Inflammatory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions In Vitro. Baer PC; Koch B; Freitag J; Schubert R; Geiger H Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936266 [TBL] [Abstract][Full Text] [Related]
33. Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes. Goodwin NC; Ding ZM; Harrison BA; Strobel ED; Harris AL; Smith M; Thompson AY; Xiong W; Mseeh F; Bruce DJ; Diaz D; Gopinathan S; Li L; O'Neill E; Thiel M; Wilson AG; Carson KG; Powell DR; Rawlins DB J Med Chem; 2017 Jan; 60(2):710-721. PubMed ID: 28045524 [TBL] [Abstract][Full Text] [Related]
34. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Gallo LA; Wright EM; Vallon V Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707 [TBL] [Abstract][Full Text] [Related]
35. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634 [TBL] [Abstract][Full Text] [Related]
36. The bark giving diabetes therapy some bite: the SGLT inhibitors. Marshall SM Diabetologia; 2018 Oct; 61(10):2075-2078. PubMed ID: 30132029 [No Abstract] [Full Text] [Related]
37. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus]. Mauricio D Med Clin (Barc); 2013 Sep; 141 Suppl 2():31-5. PubMed ID: 24444522 [TBL] [Abstract][Full Text] [Related]
38. SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus. Nathan KT; Ahmed-Sarwar N; Werner P Consult Pharm; 2016 May; 31(5):251-60. PubMed ID: 27178654 [TBL] [Abstract][Full Text] [Related]
39. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Gerich JE; Bastien A Expert Rev Clin Pharmacol; 2011 Nov; 4(6):669-83. PubMed ID: 22111852 [TBL] [Abstract][Full Text] [Related]
40. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus. Miller K; Miller EM J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]